EGFR and lung carcinoma: Although immune checkpoint inhibitors (ICIs) have revolutionized treatment strategies of lung cancer, the overall response rate of ICI monotherapies is still limited and no more than 20% in NSCLC patients with EGFR/ALK wild-type (Doroshow et al., 2019).